ebomi
The catalogIssuersInsidersTapeLicence
Colour theme
Theme
Sign in
Insider · CIK 0001542073

He Wei-Wu

CIK 0001542073 Name as filed on the most recent filing

Filed as He Wei-Wu (20)

34 transaction lines · from 20 filings · filed 2012-05-03 to 2022-06-17 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

34 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.

Transactions filed by this insider
Direction Date Issuer Code Shares Price Value USD Filing
2022-06-15 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 50,000 acquired 3.18 159,000.00 Form 4, filing 0001104659-22-072392
2022-06-14 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 2,096 acquired 3.06 6,413.76 Form 4, filing 0001104659-22-072392
2022-06-13 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 36,058 acquired 2.97 107,092.26 Form 4, filing 0001104659-22-072392
2021-11-18 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 200,000 acquired 0.98 196,000.00 Form 4, filing 0001104659-21-141867
2021-11-17 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 200,000 acquired 0.99 198,000.00 Form 4, filing 0001104659-21-141867
2021-08-19 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 180,000 acquired 1.26 226,800.00 Form 4, filing 0001104659-21-108182
2021-08-18 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 300,000 acquired 1.29 387,000.00 Form 4, filing 0001104659-21-108182
2021-03-26 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 3,000,000 acquired 2.05 6,150,000.00 Form 4, filing 0001104659-21-043957
2020-11-23 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 100,000 acquired 2.18 218,000.00 Form 4, filing 0001104659-20-129106
2020-11-20 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 127,471 acquired 2.12 270,238.52 Form 4, filing 0001104659-20-129106
2020-07-22 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 2,952,426 acquired 1.90 5,609,609.40 Form 4, filing 0001104659-20-086415
2020-07-22 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 1,200,000 acquired 1.90 2,280,000.00 Form 4, filing 0001104659-20-086415
2020-05-20 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 56,464 acquired 2.37 133,819.68 Form 4, filing 0001104659-20-064841
2020-05-19 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 29,801 acquired 2.03 60,496.03 Form 4, filing 0001104659-20-064841
2020-05-18 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 338,932 acquired 2.02 684,642.64 Form 4, filing 0001104659-20-063872
2020-05-15 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 100,000 acquired 1.82 182,000.00 Form 4, filing 0001104659-20-063872
2020-03-27 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 6,880 acquired 2.08 14,310.40 Form 4, filing 0001104659-20-040338
2020-03-26 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 328,095 acquired 2.09 685,718.55 Form 4, filing 0001104659-20-039667
2020-03-25 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 196,398 acquired 1.94 381,012.12 Form 4, filing 0001104659-20-039667
2020-03-19 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 234,488 acquired 1.57 368,146.16 Form 4, filing 0001104659-20-036022
2020-03-18 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 501,322 acquired 1.52 762,009.44 Form 4, filing 0001104659-20-036022
2020-03-17 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 264,192 acquired 1.50 396,288.00 Form 4, filing 0001104659-20-036022
2019-08-16 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 20,000 acquired 3.20 64,000.00 Form 4, filing 0001144204-19-040830
2019-08-14 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 160,000 acquired 3.17 507,200.00 Form 4, filing 0001144204-19-040279
2018-03-19 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 3,086,419 acquired 3.24 9,999,997.56 Form 4, filing 0001144204-18-016226
2017-10-10 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 100,000 acquired 1.95 195,000.00 Form 4, filing 0001144204-17-052056
2017-10-06 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 100,000 acquired 1.86 186,000.00 Form 4, filing 0001144204-17-051905
2017-10-05 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 100,000 acquired 1.80 180,000.00 Form 4, filing 0001144204-17-051905
2017-09-19 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 34,002 acquired 1.78 60,523.56 Form 4, filing 0001144204-17-048904
2017-09-18 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 173,500 acquired 1.75 303,625.00 Form 4, filing 0001144204-17-048904
2017-09-15 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 127,702 acquired 1.49 190,275.98 Form 4, filing 0001144204-17-048556
2017-09-14 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 187,625 acquired 1.22 228,902.50 Form 4, filing 0001144204-17-048556
2016-10-03 Casi Pharmaceuticals, Inc.
CASI 		P, Open-market purchase 1,871,605 acquired 1.19 2,227,209.95 Form 4, filing 0001144204-16-127052
2012-05-01 Entremed Inc
ENMD 		P, Open-market purchase 441,072 acquired Not reported Not priced Form 4, filing 0001144204-12-026006

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 34
  • Open-market sale 0
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. He Wei-Wu, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001542073

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.